CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Buprenorphine transdermal patch

Last Updated: May 9, 2011
Result type: Reports
Project Number: SR0233-000
Product Line: Reimbursement Review

Generic Name: Buprenorphine transdermal patch

Brand Name: BuTrans

Manufacturer: Purdue Pharma

Therapeutic Area: Pain, moderate intensity persistent pain

Indications: Pain, persistent (moderate intensity)

Submission Type: Resubmission

Project Status: Complete

Date Recommendation Issued: September 28, 2011

Recommendation Type: Do not list